Among these combinations, that of atezolizumab (anti-PD-L1 antibody) and bevacizumab (anti-VEGF antibody) plus chemotherapy has been reported to have efficacy in the phase 3 IMpower150 trial for non-squamous non-small cell lung cancer (5). Here, VEGFA is linked to non-small cell squamous lung carcinoma.